4.83
Cellectis Adr Borsa (CLLS) Ultime notizie
European ADRs Stay Put As Novo Nordisk Slides - Finimize
12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Moligo and Cellectis show promise in non-viral gene editing method - Investing.com India
Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications - Sahm
Why Cellectis Stock Is Trading Higher Today - Sahm
Citizens maintains Cellectis stock rating with $8 target ahead of ASH update - Investing.com
European ADRs Slip As Gains And Losses Balance Out - Finimize
European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize
Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail
Barclays raises Cellectis stock price target to $8 on promising cancer therapy - Investing.com Philippines
Jefferies raises Cellectis stock price target to $6 after R&D day - Investing.com
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Operating cash flow per share of Cellectis S.A. Sponsored ADR – LSX:A14QZE - TradingView
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
A look into Cellectis ADR (CLLS)’s deeper side - Setenews
Cellectis’s SWOT analysis: gene therapy firm’s stock poised for growth? - Investing.com
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
European Stocks In The US Close The Week Mostly Steady - Finimize
European Equities Traded in the US as ADRs Fall in Friday Trading - 富途牛牛
Biotech And Tech Firms Drive Gains For European ADRs - Finimize
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates - ADVFN Brasil
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal moment - Investing.com
Earnings call transcript: Cellectis Q2 2025 earnings miss drives stock down 13% - Investing.com
Cellectis earnings missed by $0.02, revenue topped estimates - Investing.com India
Cellectis earnings missed by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
European Stocks Dip As US Holders Turn Cautious - Finimize
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
European ADRs Inch Higher As Drugmakers Shine - Finimize
Cellectis shares surge 66% following InvestingPro’s April Fair Value alert By Investing.com - Investing.com India
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):